Zephyrm Bioscience
Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A biotech firm engineering therapeutic antibodies for cancer and immune diseases.
OncologyImmunology
Technology Platform
Employs antibody discovery and engineering platforms to generate novel monoclonal and potentially bispecific antibodies against cancer and immunological targets.
Opportunities
Potential for high-value partnerships or acquisition if its antibody platform yields a best-in-class or first-in-class candidate.
Risk Factors
High risk of scientific and clinical failure, coupled with significant funding requirements to advance programs.
Competitive Landscape
Enters a fiercely competitive arena with numerous companies pursuing similar antibody targets in oncology and immunology.